{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:13:01Z","timestamp":1788955981197,"version":"build-2803163510"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>\n                    Despite major advances in the treatment of severe asthma with biologics targeting IgE, IL-5\/IL-5R\n                    <jats:italic>\u03b1<\/jats:italic>\n                    , IL-4R\n                    <jats:italic>\u03b1<\/jats:italic>\n                    , and thymic stromal lymphopoietin (TSLP), these agents suppress type 2 inflammation without reliably inducing durable allergen-specific tolerance. Allergen immunotherapy (AIT) remains the only disease-modifying option for IgE-mediated respiratory allergy, yet its use in severe asthma has historically been restricted by safety concerns in uncontrolled disease. We propose a \u201ccontrol first, tolerance second\u201d framework, whereby biologic-induced disease control creates a window enabling safe initiation of subcutaneous or sublingual AIT. This narrative review synthesizes the immunological rationale and clinical evidence supporting sequential biologic-AIT combination, with emphasis on omalizumab as the best-studied adjunct and emerging data on dupilumab and tezepelumab. We address biomarker-guided patient selection, treatment sequencing, comorbid allergic rhinitis and chronic rhinosinusitis, corticosteroid-sparing effects, infection risk, airway antiviral immunity, and unresolved questions around long-term remission. The novelty of this framework lies in reframing biologics not merely as symptom-control agents but as facilitators that unlock a previously inaccessible disease-modifying intervention, potentially shifting severe allergic asthma management from control toward durable immunological remission. We conclude that biologic-enabled AIT is a promising but insufficiently defined strategy, and outline the prospective trials, standardized phenotyping, and safety registries needed to establish it as an evidence-based clinical pathway.\n                  <\/jats:p>","DOI":"10.3389\/falgy.2026.1942188","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:03:11Z","timestamp":1788955391000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Control first, tolerance second: biologics as enablers of allergen immunotherapy in severe allergic asthma"],"prefix":"10.3389","volume":"7","author":[{"given":"B.","family":"Jentzsch","sequence":"first","affiliation":[{"name":"Clinic of Pneumology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg","place":["Freiburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hoheisel","sequence":"additional","affiliation":[{"name":"Clinic of Pneumology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg","place":["Freiburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Gashynova","sequence":"additional","affiliation":[{"name":"Clinic of Pneumology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg","place":["Freiburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"F\u00e4hndrich","sequence":"additional","affiliation":[{"name":"Clinic of Pneumology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg","place":["Freiburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C.","family":"Frye","sequence":"additional","affiliation":[{"name":"Clinic of Pneumology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg","place":["Freiburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Alvarado Castillo","sequence":"additional","affiliation":[{"name":"Clinic of Pneumology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg","place":["Freiburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Allergy Research Group, Medical Center, University of Freiburg","place":["Freiburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Cherrez-Ojeda","sequence":"additional","affiliation":[{"name":"Universidad Espiritu Santo","place":["Samborondon, Ecuador"]},{"name":"Respiralab Research Group","place":["Guayaquil, Ecuador"]},{"name":"Institute of Allergology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Stolz","sequence":"additional","affiliation":[{"name":"Clinic of Pneumology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg","place":["Freiburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1055\/a-2070-2135","article-title":"Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023\u2014published by the German respiratory society (DGP) e.V","volume":"77","author":"Lommatzsch","year":"2023","journal-title":"Pneumologie"},{"key":"B3","year":""},{"key":"B4","doi-asserted-by":"publisher","first-page":"240088","DOI":"10.1183\/16000617.0088-2024","article-title":"Biologics in severe asthma: a state-of-the-art review","volume":"34","author":"Gyawali","year":"2025","journal-title":"Eur Respir Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJM199908123410702","article-title":"Long-term clinical efficacy of grass-pollen immunotherapy","volume":"341","author":"Durham","year":"1999","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40413-015-0063-2","article-title":"Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens","volume":"8","author":"Akdis","year":"2015","journal-title":"World Allergy Organ J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5414\/ALX02331E","article-title":"Guideline on allergen immunotherapy in IgE-mediated allergic diseases: s2\u2005K guideline","volume":"6","author":"Pfaar","year":"2022","journal-title":"Allergol Select"},{"key":"B8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13223-024-00935-2","article-title":"Allergen immunotherapy","volume":"20","author":"Boursiquot","year":"2024","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/all.13749","article-title":"EAACI Guidelines on allergen immunotherapy: house dust mite-driven allergic asthma","volume":"74","author":"Agache","year":"2019","journal-title":"Allergy"},{"key":"B10","year":""},{"key":"B11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.anai.2024.06.016","article-title":"The combination of allergen immunotherapy and biologics for inhalant allergies: exploring the synergy","volume":"134","author":"Olivieri","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.jaip.2025.05.003","article-title":"Combination of allergen-specific immunotherapy with biologics in severe asthma: counterintuitive or rational?","volume":"13","author":"Larenas-Linnemann","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma","volume":"16","author":"Lambrecht","year":"2015","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12931-018-0813-0","article-title":"Is IgE or eosinophils the key player in allergic asthma pathogenesis?","volume":"19","author":"Matucci","year":"2018","journal-title":"Respir Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jaci.2007.06.013","article-title":"Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation","volume":"120","author":"Bohle","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc\u03b5RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jaci.2005.09.036","article-title":"Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis","volume":"117","author":"Casale","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jaci.2009.11.022","article-title":"Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma","volume":"125","author":"Massanari","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"B22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.4168\/aair.2024.16.6.682","article-title":"Combined dupilumab and allergen-specific immunotherapy in severe refractory atopic dermatitis","volume":"16","author":"Kim","year":"2024","journal-title":"Allergy Asthma Immunol Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1698053","DOI":"10.3389\/falgy.2025.1698053","article-title":"Case report: dupilumab combined with allergen-specific immunotherapy in severe atopic dermatitis and asthma","volume":"6","author":"Tussupbekova","year":"2025","journal-title":"Front Allergy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/cea.14256","article-title":"Efficacy of tezepelumab in patients with evidence of severe allergic asthma: results from the phase 3 NAVIGATOR study","volume":"53","author":"Corren","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"220144","DOI":"10.1183\/16000617.0144-2022","article-title":"Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD","volume":"32","author":"Calderon","year":"2023","journal-title":"Eur Respir Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2147\/JAA.S318892","article-title":"Short-Term subcutaneous allergy immunotherapy and dupilumab are well tolerated in allergic rhinitis: a randomized trial","volume":"14","author":"Corren","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.alit.2022.05.010","article-title":"Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis","volume":"71","author":"Hoshino","year":"2022","journal-title":"Allergol Int"},{"key":"B31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial","volume":"151","author":"Corren","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2222.2008.03121.x","article-title":"Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma","volume":"39","author":"Kopp","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1111\/j.1399-3038.2009.00900.x","article-title":"Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously","volume":"21","author":"Kamin","year":"2010","journal-title":"Pediatr Allergy Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02770903.2026.2660096","article-title":"Three years treatment with HDM allergen immunotherapy, omalizumab, or combination therapy in allergic asthma: clinical outcomes and biomarkers","author":"Bozek","year":"2026","journal-title":"J Asthma"},{"key":"B35","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/alr.23268","article-title":"Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: a meta-analysis of randomized controlled trials","volume":"14","author":"Zhang","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"00639-2022","DOI":"10.1183\/23120541.00639-2022","article-title":"Adding a biologic to allergen immunotherapy increases treatment efficacy","volume":"9","author":"Bo\u017cek","year":"2023","journal-title":"ERJ Open Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1080\/02770903.2023.2293057","article-title":"Progressive clinical effects of the combination omalizumab and HDM - allergen immunotherapy in asthma","volume":"61","author":"Bozek","year":"2024","journal-title":"J Asthma"},{"key":"B38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/pai.12306","article-title":"Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma","volume":"25","author":"Lambert","year":"2014","journal-title":"Pediatr Allergy Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/cea.13084","article-title":"The use of omalizumab in allergen immunotherapy","volume":"48","author":"Dantzer","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"B40","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis","volume":"13","author":"Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/pai.12563","article-title":"EAACI Molecular allergology User's Guide","volume":"27","author":"Matricardi","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J Asthma Allergy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"key":"B45","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/antiox12020400","article-title":"Exploring the interaction between fractional exhaled nitric oxide and biologic treatment in severe asthma: a systematic review","volume":"12","author":"Pianigiani","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/pai.12098","article-title":"Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy","volume":"24","author":"Kopp","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/all.12698","article-title":"The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease","volume":"70","author":"Hoffmann","year":"2015","journal-title":"Allergy"},{"key":"B49","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/all.12627","article-title":"Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells","volume":"70","author":"Contoli","year":"2015","journal-title":"Allergy"},{"key":"B50","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1164\/rccm.201701-0120OC","article-title":"Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma","volume":"196","author":"Esquivel","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.jaci.2017.07.035","article-title":"Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab","volume":"141","author":"Gill","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"100726","DOI":"10.1016\/j.waojou.2022.100726","article-title":"Systemic corticosteroids in asthma: a call to action from world allergy organization and respiratory effectiveness group","volume":"15","author":"Bleecker","year":"2022","journal-title":"World Allergy Organ J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.jaci.2015.05.044","article-title":"The airway microbiome in patients with severe asthma: associations with disease features and severity","volume":"136","author":"Huang","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jaci.2016.08.055","article-title":"Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment","volume":"140","author":"Durack","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e14095","DOI":"10.1111\/pai.14095","article-title":"Influence of the gut and airway microbiome on asthma development and disease","volume":"35","author":"Smulders","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1454333","DOI":"10.3389\/fcimb.2024.1454333","article-title":"Allergen-specific sublingual immunotherapy altered gut microbiota in patients with allergic rhinitis","volume":"14","author":"Wu","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2300819","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK severe asthma registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"key":"B58","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1002\/ohn.648","article-title":"Clinical practice guideline: immunotherapy for inhalant allergy","author":"Gurgel","year":"2024","journal-title":"Otolaryngol Head Neck Surg"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1942188\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:03:12Z","timestamp":1788955392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1942188\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":58,"alternative-id":["10.3389\/falgy.2026.1942188"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1942188","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1942188"}}